MarketCapExport financials
Conformis (CFMS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Conformis Financial Ratios 2022-2011 | CFMS
Brief overview of Conformis's financial ratios
Ratios are assessed across five available annual reports in the 2018–2022 interval.
The latest available valuation ratios are P/S 0.2x (median 1.05x), P/B 0.23x (median 2x). Valuation is roughly 84.5% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.
Returns on assets and capital are represented by ROE -93.2%, ROA -53.7%, ROCE -85.4%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
A shorter cycle, from 264.4 days to 165.4 days, indicates faster release of cash from operations.
Valuation takeaway
Conformis trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.
Annual Financial Ratios Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.3 | -1.8 | -3.0 | -9.2 | -7.3 | -5.0 | -3.6 | -3.5 | - | - | - | - |
P/S |
0.2 | 0.0 | 1.1 | 2.5 | 3.3 | 2.8 | 9.6 | 3.0 | - | - | - | - |
EPS |
-7.0 | -0.4 | -0.3 | -0.4 | -0.7 | -1.2 | -1.4 | -2.6 | -10.8 | -12.0 | - | - |
EV (Enterprise Value) |
3.84 M | -51.5 M | 104 M | 79.6 M | 82.8 M | 87.9 M | 190 M | 101 M | -16.4 M | -39.3 M | - | - |
EBITDA per Share |
-5.85 | 0.19 | -0.29 | -0.33 | -0.59 | -1.2 | -1.28 | -2.43 | -10.2 | -11.4 | - | - |
EV/EBITDA |
-0.1 | -40.7 | -5.0 | -3.8 | -2.4 | -1.7 | -3.6 | -1.9 | 0.4 | 0.9 | - | - |
PEG |
0.0 | 0.03 | 0.09 | 0.2 | 0.19 | -0.11 | -0.13 | 0.06 | - | - | - | - |
P/B |
0.2 | 0.0 | 6.4 | 3.1 | 2.0 | 1.3 | 2.2 | 1.4 | - | - | - | - |
P/CF |
-0.3 | -0.5 | -4.0 | -17.6 | -2.9 | -1.5 | -6.0 | -4.1 | - | - | - | - |
ROE % |
-93.16 | -2.40 | -213.62 | -33.24 | -27.27 | -25.49 | -61.23 | -40.54 | -91.76 | -69.44 | - | - |
ROA % |
-53.67 | -1.66 | -33.98 | -7.50 | -15.67 | -12.64 | -51.05 | -35.92 | -64.15 | -57.08 | - | - |
ROCE % |
-85.42 | -2.99 | -61.88 | -46.07 | -74.97 | -69.05 | -56.98 | -38.27 | -75.15 | -67.15 | - | - |
Current Ratio |
2.4 | 3.2 | 1.2 | 1.3 | 2.4 | 2.0 | 6.0 | 8.8 | 3.3 | 5.6 | - | - |
DSO |
55.4 | 32.1 | 52.0 | 223.0 | 218.5 | 245.2 | 248.8 | 65.4 | 34.5 | - | - | - |
DIO |
160.3 | 148.4 | 128.4 | 96.9 | 82.7 | 77.4 | 79.7 | 77.7 | 43.4 | - | - | - |
DPO |
50.4 | 61.3 | 61.6 | 46.5 | 36.8 | 38.4 | 35.0 | 33.7 | 20.4 | - | - | - |
Operating Cycle |
215.8 | 180.5 | 180.4 | 319.9 | 301.2 | 322.5 | 328.5 | 143.2 | 77.9 | - | - | - |
Cash Conversion Cycle |
165.4 | 119.2 | 118.8 | 273.4 | 264.4 | 284.2 | 293.5 | 109.5 | 57.5 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.78 | -1.32 | - | -0.08 | -0.09 | -0.09 | - | -0.07 | 0.21 | -0.09 | -0.08 | -0.09 | -0.03 | -0.14 | -0.08 | -0.13 | -0.11 | -0.12 | -0.16 | -0.12 | -0.24 | -0.22 | -0.27 | -0.29 | -0.28 | -0.4 | -0.37 | -0.31 | -0.34 | -0.37 | -0.37 | -0.45 | -2.51 | -3.32 | -2.83 | -2.44 | -2.49 | -3.04 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.43 | -1.17 | - | -0.05 | -0.06 | -0.08 | - | -0.05 | 0.19 | -0.06 | - | -0.05 | - | -0.1 | - | -0.06 | -0.06 | -0.09 | - | -0.06 | -0.16 | -0.21 | - | -0.23 | -0.28 | -0.38 | - | -0.25 | -0.3 | -0.35 | - | -0.38 | -2.23 | -3.15 | - | -2.06 | -2.24 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-108.07 | -86.08 | -64.64 | -75.95 | -20.84 | -12.87 | 5.77 | -52.46 | -74.03 | -129.57 | -214.69 | -189.70 | -200.54 | -200.03 | -126.68 | -120.71 | -94.10 | -97.92 | -92.87 | -91.10 | -95.90 | -85.02 | -86.63 | -77.87 | -68.14 | -62.57 | -52.79 | -46.67 | -45.51 | -72.92 | -71.28 | -85.01 | -94.85 | -76.46 | -24.34 | -20.86 | -21.16 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-58.65 | -51.90 | -40.22 | -48.45 | -11.38 | -6.02 | 6.43 | -2.83 | -2.33 | -28.03 | -34.87 | -33.11 | -37.25 | -44.50 | -41.59 | -49.75 | -46.50 | -51.02 | -50.74 | -47.71 | -51.05 | -46.55 | -50.09 | -51.40 | -50.03 | -50.41 | -45.58 | -41.03 | -40.29 | -48.31 | -47.02 | -54.63 | -59.37 | -55.34 | -17.02 | -14.59 | -14.79 | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-96.52 | -75.23 | -54.10 | -64.01 | -19.84 | -12.95 | 4.19 | -33.41 | -50.70 | -160.14 | -149.66 | -184.09 | -168.07 | -162.57 | -77.70 | -92.69 | -81.35 | -80.43 | -58.73 | -81.42 | -86.80 | -85.45 | -64.79 | -77.11 | -66.61 | -58.07 | -36.33 | -46.78 | -73.93 | -71.70 | -59.88 | -80.61 | -91.27 | -9.96 | - | -20.73 | -21.11 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.9 | 2.2 | 2.4 | 2.4 | 2.7 | 3.0 | 3.2 | 3.7 | 3.9 | 2.5 | 1.2 | 1.3 | 1.1 | 1.2 | 1.3 | 1.4 | 1.7 | 1.9 | 2.4 | 2.0 | 2.1 | 2.4 | 2.0 | 2.2 | 2.4 | 3.3 | 6.0 | 7.7 | 9.1 | 7.9 | 8.8 | 9.3 | 1.9 | 8.8 | 3.3 | 3.3 | 3.3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
56.9 | 65.1 | - | 62.9 | 58.7 | 56.4 | - | 57.1 | 13.9 | 55.1 | 47.8 | 48.6 | 38.3 | 53.4 | 49.5 | 57.3 | 56.5 | 57.9 | 51.5 | 37.6 | 58.1 | 58.7 | 56.7 | 60.6 | 61.5 | 61.9 | 60.0 | 65.9 | 62.8 | 64.0 | 55.3 | 63.3 | 61.5 | 74.5 | 58.5 | 69.3 | 37.2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
157.1 | 226.5 | - | 177.6 | 150.2 | 143.5 | - | 154.7 | 138.6 | 154.4 | - | 141.1 | 135.2 | 117.9 | - | 104.7 | 92.4 | 80.6 | - | 94.2 | 78.7 | 72.9 | - | 91.8 | 86.4 | 75.5 | - | 85.6 | 81.8 | 80.9 | - | 88.4 | 89.4 | 93.4 | - | 95.5 | 49.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
31.6 | 49.1 | - | 70.2 | 57.2 | 54.5 | - | 55.8 | 51.6 | 59.1 | - | 64.1 | 68.2 | 64.6 | - | 41.4 | 39.5 | 33.3 | - | 51.5 | 47.4 | 39.0 | - | 38.6 | 40.4 | 36.7 | - | 23.9 | 27.2 | 36.1 | - | 45.8 | 39.5 | 40.5 | - | 44.9 | 23.3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
213.9 | 291.7 | - | 240.5 | 208.9 | 199.9 | - | 211.8 | 152.5 | 209.5 | 46.5 | 184.3 | 175.8 | 175.8 | 50.9 | 172.2 | 162.0 | 144.8 | 54.7 | 135.6 | 150.4 | 139.9 | 58.0 | 140.8 | 133.7 | 130.5 | 61.8 | 156.4 | 149.5 | 144.6 | 71.1 | 192.1 | 162.8 | 167.8 | 58.5 | 164.8 | 86.7 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
182.3 | 242.5 | - | 170.3 | 151.7 | 145.4 | - | 156.0 | 100.9 | 150.4 | 46.5 | 131.1 | 122.7 | 117.5 | 50.9 | 107.0 | 98.7 | 101.1 | 54.7 | 101.7 | 118.9 | 105.0 | 58.0 | 100.6 | 97.2 | 96.6 | 61.8 | 116.9 | 112.0 | 110.4 | 71.1 | 153.4 | 125.0 | 127.3 | 58.5 | 119.9 | 63.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Conformis, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 100.1 | 2.67 % | $ 174 B |  USA |
 |
Aethlon Medical
AEMD
|
$ 6.53 | 1.16 % | $ 4.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.74 | 2.5 % | $ 776 M | USA |
 |
Align Technology
ALGN
|
$ 140.65 | 0.1 % | $ 10.2 B | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.6 | 1.96 % | $ 107 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.3 | 7.37 % | $ 36.8 M | USA |
 |
Alphatec Holdings
ATEC
|
$ 10.72 | 6.88 % | $ 1.61 B | USA |
 |
AxoGen
AXGN
|
$ 37.22 | 0.21 % | $ 1.71 B | USA |
 |
Butterfly Network
BFLY
|
$ 9.38 | 4.8 % | $ 2.32 B | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 379.82 | 2.89 % | $ 10.4 B | USA |
 |
Bruker Corporation
BRKR
|
$ 63.86 | 0.98 % | $ 9.69 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 42.4 | 0.31 % | $ 62.8 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.77 | 0.34 % | $ 639 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 11.52 | 5.74 % | $ 326 M | USA |
 |
CONMED Corporation
CNMD
|
$ 47.33 | 2.25 % | $ 1.47 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 3.97 | 0.12 % | $ 247 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.87 | 4.89 % | $ 568 M | USA |
 |
Electromed
ELMD
|
$ 28.32 | 0.78 % | $ 234 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 66.47 | 3.76 % | $ 1.97 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 87.23 | 2.44 % | $ 51 B | USA |
 |
Globus Medical
GMED
|
$ 76.57 | 1.28 % | $ 10.4 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.65 | 0.76 % | $ 58.4 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 13.29 | 4.81 % | $ 1.02 B | USA |
 |
Inogen
INGN
|
$ 5.94 | 0.34 % | $ 158 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.13 | 0.28 % | $ 913 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 70.75 | 1.11 % | $ 2.08 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.69 | 7.28 % | $ 11.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.47 | 1.25 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.45 | 0.1 % | $ 4.39 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
$ 22.89 | 3.29 % | $ 537 M | USA |
 |
LivaNova PLC
LIVN
|
$ 76.43 | 1.81 % | $ 4.17 B |  Britain |
|
LENSAR
LNSR
|
$ 6.67 | 0.59 % | $ 79.8 M | USA |
 |
Pulmonx Corporation
LUNG
|
$ 1.88 | 2.73 % | $ 76.5 M | USA |
 |
Medtronic PLC
MDT
|
$ 87.97 | 1.88 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.55 | 0.54 % | $ 672 M | USA |
 |
Myomo
MYO
|
$ 1.67 | 2.45 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.64 | 1.15 % | $ 41.5 M | Israel |
 |
InspireMD
NSPR
|
$ 0.58 | 1.64 % | $ 37.3 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.5 | 4.51 % | $ 376 M |  Curacao |
 |
Outset Medical
OM
|
$ 4.1 | 3.54 % | $ 62.4 K | USA |
 |
PAVmed
PAVM
|
$ 2.66 | 4.36 % | $ 1.78 M | USA |
 |
Penumbra
PEN
|
$ 317.11 | 0.07 % | $ 12.3 B | USA |
 |
Insulet Corporation
PODD
|
$ 135.62 | 2.98 % | $ 9.54 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 6.03 | 3.25 % | $ 182 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.81 | 4.67 % | $ 162 M | USA |
 |
AVITA Medical
RCEL
|
$ 13.25 | 4.17 % | $ 369 M |  Australia |
 |
Sintx Technologies
SINT
|
$ 2.18 | 1.05 % | $ 6.05 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.92 | 1.87 % | $ 23.3 B | Britain |
 |
Sensus Healthcare
SRTS
|
$ 2.92 | 0.34 % | $ 47.7 M | USA |
 |
Stryker Corporation
SYK
|
$ 285.22 | 3.54 % | $ 109 B | USA |